1
TITLE: ENDURANCE-2: Safety and Efficacy of ABT-493/ABT-530 in Hepatitis C Virus Genotype 2-infected Patients without Cirrhosis, a Randomized, Double-Blind, Placebo-Controlled Study  Full Text
AUTHORS: Kris V Kowdley; Massimo Colombo; Neddie Zadeikis; Parvez S Mantry; Filipe Calinas; Humberto I Aguilar; Victor de Ledinghen; Yves J Horsmans; Yiran R Hu; Teresa Ng; Federico Mensa;
PUBLISHED: 2016, SOURCE: 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) in HEPATOLOGY, VOLUME: 64
INDEXED IN: WOS
2
TITLE: STARTVerso3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection  Full Text
AUTHORS: Ira M Jacobson; Tarik Asselah; Peter Ferenci; Graham R Foster; Donald M Jensen; Francesco Negro; Parvez S Mantry; David Wright; Xavier Forns; Javier Garcia Samaniego; Celia Oliveira; Armando Carvalho; Daniel M Forton; Kosh Agarwal; Keikawus Arasteh; Curtis Cooper; Wayne Ghesquiere; Jean Francois Dufour; Yoshiyuki Sakai; Yasuhito Tanaka; Jerry O Stern; Nanshi S Sha; Wulf O Boecher; Gerhard G Steinmann; Anne Marie Quinson; ...More
PUBLISHED: 2013, SOURCE: 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases in HEPATOLOGY, VOLUME: 58
INDEXED IN: WOS